Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.375 -3.0% 12.125 93,718 08:10:34
Bid Price Offer Price High Price Low Price Open Price
12.00 12.25 12.625 12.125 12.625
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -7.24 -4.46 25
Last Trade Time Trade Type Trade Size Trade Price Currency
08:11:25 O 10,000 12.005 GBX

Futura Medical (FUM) Latest News

More Futura Medical News
Futura Medical Takeover Rumours

Futura Medical (FUM) Discussions and Chat

Futura Medical Forums and Chat

Date Time Title Posts
11/12/201922:39FUTURA a winner for 20156,662
10/12/201915:46fum reality7
08/7/201908:08one million2
02/12/201613:27FUM delivering on sex,pain and rock'n'roll11,414

Add a New Thread

Futura Medical (FUM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Futura Medical trades in real-time

Futura Medical (FUM) Top Chat Posts

Futura Medical Daily Update: Futura Medical Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 12.50p.
Futura Medical Plc has a 4 week average price of 7.75p and a 12 week average price of 7.75p.
The 1 year high share price is 49p while the 1 year low share price is currently 5.50p.
There are currently 204,660,267 shares in issue and the average daily traded volume is 9,987,988 shares. The market capitalisation of Futura Medical Plc is £25,838,358.71.
petroc: Partially agree, Madmonkflin. It's binary in the sense we either make money or we don't, but I think the 19/20 positive results muddy the water, if true. It seems to me that if Ph3 is a fail, the price will crash, but if it isn't, there'll be a sliding scale of success, with the share price possibly climbing slightly (or even dropping)on the low side of positive results; to sky high if all 19 endpoints are met. If there are 19 positive scenarios, then the chances are the result will average out, and we get a moderate return on our investment. The only upside is that risk is reduced in a 19/20 situation, BUT bearing in mind the adage, the higher the risk, the higher the return, we have the opposite scenario here, i.e. the lower the risk, the lower the return. Hope I'm wrong though!
bg23: there seems to be a common misconception here that the results of the phase 3 trial are known. Sure I understand there is a lot of positive analyst comment around, along with fireside chats and these BB's, but to assume that the news is out and is going to have a positive effect in the share price rather denies normal market experience. from the little I know about the med's being tested, they seem to have previously had positive results - so no real surprise if we get a result that proves positive for useage on the male undercarriage. but realistically, that's not what is being anticipated here. The company has been running the tests as it couldn't previously encourage a large pharma or financier to underwrite the cost for them. the results if positive are HOPED to be the trigger for a successful partnership or engagement with a larger, richer party that will either finance, develop or even buy the company. so that's the market concern. are the results good enough to be able to attract a larger group to the party without further fundraising against existing shareholders - and we have to say, on past experience of current management, they have a lot to prove! to assume like Utyinv above that this is a one way trade is both naïve and unrealistic. referencing 'Leaked news' also implies a naivety on the process of pricing and information dissemination. assuming we all know (or assume we know) positive news is available and will be announced soon is dangerous to the wallet of the smaller, inexperienced investor. as a long term shareholder - I have them at an average north of 40p - I realise that this is not a binary heads or tails. Despite some of the commentary on this and the majority of BB's, I hope others do also.
siriusbizness: You know what they say about stats. The Company will present those that show the best results for med2005. That will really set the size of the market available. Either way if only just mild ED and it can be a primary treatment then it’s huge. I am more interested in the funding. Couple of options available. Placing (maybe private) at higher share price as they did post phase 2 study. I like this as it means the Company don’t give too much away too soon. Partnership with up front and milestone payments is the other option. This is what the Company has been looking at for years but really depends on the phase 3 results to get the best deal. Either option sees a much higher share price so sit tight and let’s see.
j777j: My own view is the share price could reach Liberum's 60p price target upon news of completion of Phase 3 trials in a few days time. As this will be the most significant milestone in the company's history to date. If the trial results in december are a success the share price could head well over 100p.Liberum reckon 145p. Not long to wait. GLA to all patient holders.
duwendag: Thebutler and his alter ego Jonnybig should be reported as being one of the same, he must have a short on this stock as well with Iofin. He's Fxxked up on Iofina as their share price has doubled from 15p to 30p so lets hope the same happens with FUM. Theirs nothing wrong in a reasoned argument and discussion for or against a stock, but blatant lying to short a stock is despicable as he has done with Iofin and FUM, all I can say is "karma"
glavey: "According to Liberum a successful phase 3 will lead to a 95p share price..." Where do Liberum write that it will lead to a 95p share price?
lbo: Such a fantastic opportunity that the partner who was supposedly in advanced discussions in March 2018 when the share price was 40p and then completely disappeared and now even at the supposed bargain of 10p has not reappeared with a bid. Never mind even buying shares in the 7p fundraising which was undersubscribed.Mr Barder then backtracked in September and October 2018 and said that raising funds and carrying out phase 3 would add 50% more value to the Med2002 licensing deal yet all the while the share price collapsed from 40p to 7p. So Futura management now need to add 400% in share price value to just get it back to the share price where they claimed they were in advanced discussions with a partner and then claimed by raising funds and completing phase 3 they would add 50% more value to the licensing deal.
j777j: Something for the weekend courtesy Gold dust on lse goldust881,179 posts Potential share price for Futura ? What is the future for Futura's share price. I have detailed below, from info in the results and more particularly from the webcast presentations what news Futura expects to announce during 2018, of which there is quite a lot that will affect the share price. MED2000-Securing of major commercial deal. CSD500-Reasignment of Rights for most of Europe and USA CSD500-Launch in 6 more countries and possibly up to 13. TPR100 & TIB200 -securing of further deals in USA/Europe. So what about the share price. Clearly there is massive potential if all the products end up all on sale at once but leading up to that point I think that announcements of each of the above this year will increase the share price as each one will confirm that progress is being made, some more than others. Clearly with any deal being announced one can expect upfront deal fees which can be substantial and this is what Futura expect as they stated at the results seminar they have no need to raise further cash. Looking at other company deals in these sectors the total upfront fees could easily be in the ?25-40 million range. So what could Futura be worth in a couple of years time. From global sales figures provided by Futura we have the following potential for Futura's market share and earnings. MED 2000 ($1 billion per annum)= ?800 million say @5% royalty is ?40 million pa TPR100 & TIB200 (1/2 billion per annum)=?400 million say @5% royalty is ?20 million pa CSD500 @10% market share of a $6billion pa market is $600 million=?450 million @ 5% royalty rate is ?9 million per annum. That totals to ?69 million per annum. That's the potential. So with an income of that size with minimal overheads the company on a p/e of 10 % would be valued at ?690 million or ?5.56 per share Current company value @ 47p today is appx 57million So the potential is 10 times the current share price. With lots of news this year we could easily see the share price double up with the newsflow and a big bucks rise coming after the current MED 2000 trial results due shortly. News may come at any time so it's a buy at this price now in my view with results due out on 14th March. If any of one of these major deals comes of the share price would double.. Clearly another investor who has done the maths and sees a ten bagger from here.
mikethebike4: james 'There will also be many new launches of the condom within the next 6 months which will help with the profile and see FUM Share price the next 6 months are most interesting and the best time to be in here. - I have seen this written so many times over the last few years - I will be so shocked when it actually happens I will probably climax on the spot without the aid of Blue Diamond ! - 18 months product is already available from TTK in Asia - why they did not submit for regulatory approval at the same time in Europe I do not know - however I am expecting an announcement by the BoD so that the AGM is not a 'damp squib' MTB4
jamesd888: There will also be many new launches of the condom within the next 6 months which will help with the profile and see FUM Share price the next 6 months are most interesting and the best time to be in here.
Futura Medical share price data is direct from the London Stock Exchange
Your Recent History
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191212 08:26:28